TABLE 1.

HLA class I allele restriction and demographic and clinical data of MS brain tissue donors

Donor IDa	Donor HLA class I allele(s)	Sex/age at deathb (yr)	Age at onset (yr)	Disease duration (yr)	Therapyc	Cause of deathd	Postmortem delay (h)
MS79	A*0201	F/49	25	24	Courses of ACTH, azathioprine, and methylprednisolone over 2 yr	MS	7
MS92	B*0801	F/37	20	17	None reported	MS	26
MS121	B*0801	F/49	35	14	Methylprednisolone for 1 yr	MS	24
MS154	B*0801	F/35	23	12	None reported	MS	12
MS180	B*0801	F/44	26	18	None reported	MS	9
MS234	B*0801	F/39	24	15	None reported	MS	15
MS286	A*0201	M/46	30	16	None reported	MS	7
MS289	A*0201, B*0702	M/45	27	18	None reported	MS	9
MS330	B*0702	F/59	20	39	None reported	MS	21
MS342	A*0201, B*0702	F/35	30	5	None reported	MS	9
MS352	B*0801	M/43	25	18	Methylprednisolone and alemtuzumab (one course each) 10 yr before death	MS	26
MS356	B*0702	F/45	29	16	None reported	MS	10

^aAll MS donors were in the progressive phase of the disease.

^bF, female; M, male.

^cACTH, adrenocorticotropic hormone.

^dMS is stated as a cause of death where death occurred as a direct result of MS or any related disability.